Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/143539
Registo completo
Campo DCValorIdioma
dc.creatorFonseca, C
dc.creatorBrito, D
dc.creatorBranco, P
dc.creatorFrazão, JM
dc.creatorSilva-Cardoso, J
dc.creatorBettencourt, P
dc.date.accessioned2022-08-29T14:35:36Z-
dc.date.available2022-08-29T14:35:36Z-
dc.date.issued2020
dc.identifier.issn0870-2551
dc.identifier.urihttps://hdl.handle.net/10216/143539-
dc.description.abstractIntroduction and Objectives: Renin-angiotensin-aldosterone system inhibitors (RAASi) are the cornerstone of treatment of heart failure with reduced ejection fraction (HFrEF). RAASi optimization in real-life care is challenged by hyperkalemia, a potentially fatal adverse event, which can necessitate downtitration or discontinuation of RAASi and negatively impact survival in HFrEF. The literature on this problem is sparse. We performed a systematic review of studies on HFrEF to investigate the prevalence, incidence, and risk factors of hyperkalemia, RAASi prescription rates, frequency of RAASi downtitration or discontinuation due to hyperkalemia, and the potential negative effect of the latter on prognosis. Methods: We conducted a MEDLINE (PubMed) search including observational and interventional studies published between January 1987 and May 2018. Results: A total of 30 observational and 18 interventional studies were included in the review. The incidence of hyperkalemia reported was between 0% and 63% in observational studies and was between 0% and 30% in clinical trials. Risk factors for hyperkalemia included RAASi prescription, older age, diabetes, and chronic kidney disease. In real-life studies, RAASi were downtitrated or discontinued in 3-22% of HFrEF patients; hyperkalemia was the reported cause in 5% of cases. No reports were found on the impact on prognosis of RAASi downtitration or discontinuation due to hyperkalemia. Conclusions: Hyperkalemia and RAASi downtitration or discontinuation are frequent, particularly in real-life HFrEF studies. Further research is needed to clarify the role of RAASi downtitration or discontinuation due to hyperkalemia and to assess its long-term prognostic impact in HFrEF patients.
dc.description.sponsorshipThis work was supported by OM Pharma (Amadora, Portugal) for the payment of medical writing support. OM Pharma had no role in the study design, or in the collection, analysis and interpretation of data, or in the writing of the manuscript, or the decision to submit the manuscript for publication. The views expressed in the manuscript are those of the authors and not necessarily those of OM Pharma.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofRevista Portuguesa de Cardiologia, vol.39(9), p. 517-541
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectClinical decision-making
dc.subjectClinical outcomes
dc.subjectDrug therapy
dc.subjectHeart failure
dc.subjectHyperkalemia
dc.subjectRenin-angiotensin-aldosterone system inhibitors
dc.subject.meshAged
dc.subject.meshAngiotensin Receptor Antagonists
dc.subject.meshAngiotensin-Converting Enzyme Inhibitors
dc.subject.meshHeart Failure / drug therapy
dc.subject.meshHumans
dc.subject.meshHyperkalemia
dc.subject.meshRenin-Angiotensin System / drug effects
dc.subject.meshStroke Volume
dc.titleHyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.1016/j.repc.2020.03.015
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0870255120303474?via%3Dihub
Aparece nas coleções:I3S - Artigo em Revista Científica Internacional

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
10.1016-j.repc.2020.03.015.pdf1.59 MBAdobe PDFThumbnail
Ver/Abrir


Este registo está protegido por Licença Creative Commons Creative Commons